GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...
A regimen based on Jazz Pharma and PharmaMar's Zepzelca and Roche's Tecentriq has been approved in the US as a maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). The approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback